H3b-6527-G000-101- An Open-Label Multicenter Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of H3b-6527 In Subjects With Advanced Hepatocellular Carcinoma Or Intrahepatic Cholangiocarcinoma
Posted Date: May 15, 2019
- Investigator: John Morris
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to determine the maximum tolerated dose of H3B-6527 in subjects with advanced liver cancer and assess the safety and tolerability of H3B-6527 as a single agent administered orally
Criteria:
To Be Eligible: Must Have Advanced Liver Cancer, Age 18 Or Older, Fgf19+, Nonpregnant/Breastfeeding, No Other Malignancy Or Infection
Keywords:
Hepatocellular Carcinoma, Cancer, Liver Cancer, Liver, Phase I
For More Information:
Uc Cancer Center
(513) 584-7698
cancer@uchealth.com